淋巴管肌瘤病:发病机制、临床特征、诊断与管理
淋巴管肌瘤病(LAM)是一种女性低度恶性、转移性肿瘤,特征为异常平滑肌样细胞浸润肺实质导致囊性肺破坏。该病由TSC基因突变引起mTOR通路持续激活,导致细胞增殖失调和淋巴管生成异常。近二十年LAM的基础与临床研究取得重要进展,包括分子机制、生物标志物、治疗策略和临床指南。
要点
- LAM是一种女性低度恶性、转移性肿瘤,导致囊性肺破坏和呼吸衰竭。
- TSC基因突变引起mTOR通路持续激活,是LAM的核心发病机制。
- mTORC1抑制剂是有效治疗策略,但需优化使用并探索新疗法。
核心结论
- LAM是一种由TSC基因突变驱动mTOR通路激活的女性低度恶性、转移性肿瘤,近二十年在机制、诊断、治疗和指南方面取得重要进展。
主要发现
- LAM的特征是异常平滑肌样细胞浸润肺实质,导致囊性肺破坏。
- LAM细胞携带TSC基因突变,引起mTOR通路持续激活、细胞增殖失调和淋巴管生成异常。
- 近二十年LAM的分子机制、诊断和预后生物标志物、治疗策略及临床实践指南均有重要进展。
临床怎么用
- mTORC1抑制剂可用于治疗LAM,但需优化其使用。
局限性
- LAM的自然病史仍需进一步研究。
- 需要开发更强大的诊断、预后和预测生物标志物。
- 需要探索诱导缓解的新疗法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lymphangioleiomyomatosis (LAM) is a slowly progressive, low-grade, metastasising neoplasm of women, characterised by infiltration of the lung parenchyma with abnormal smooth muscle-like cells, resulting in cystic lung destruction. The invading cell in LAM arises from an unknown source and harbours mutations in tuberous sclerosis complex (TSC) genes that result in constitutive activation of the mechanistic target of rapamycin (mTOR) pathway, dysregulated cellular proliferation, and a programme of frustrated lymphangiogenesis, culminating in disordered lung remodelling and respiratory failure. Over the past two decades, all facets of LAM basic and clinical science have seen important advances, including improved understanding of molecular mechanisms, novel diagnostic and prognostic biomarkers, effective treatment strategies, and comprehensive clinical practice guidelines. Further research is needed to better understand the natural history of LAM; develop more powerful diagnostic, prognostic, and predictive biomarkers; optimise the use of inhibitors of mTOR complex 1 in the treatment of LAM; and explore novel approaches to the development of remission-inducing therapies.
引用
- McCarthy C, Gupta N, Johnson SR, et al. Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management. Lancet Respir Med. 2021. PMID: 34461049. doi:10.1016/S2213-2600(21)00228-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。